Stay updated with breaking news from Main Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests of liver injury/inflammation and...
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with
(RTTNews) - Biopharmaceutical company 89bio, Inc. (ETNB) announced Monday positive topline data from the blinded extension phase of its Phase 2b E...
We're near the bottom!
We're near the bottom!